|Dr. Shankar Musunuri M.B.A., MBA, Ph.D.||Co-Founder, Chairman & CEO||845.2k||6.67M||1964|
|Dr. Uday B. Kompella Ph.D.||Co-founder & Independent Director||44k||N/A||1967|
|Dr. Vijay Tammara Ph.D.||Sr. VP of Regulatory & Quality||490.92k||575.63k||1960|
|Ms. Jessica Crespo CPA, CPA||Chief Accounting Officer, Sr. VP of Fin. and VP of Corp. Controller & Treasurer||N/A||N/A||1977|
|Dr. Arun Upadhyay Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Tiffany Hamilton M.B.A.||Head of Corp. Communications||N/A||N/A||N/A|
|Ms. Zara Gaudioso||AVP, Head of HR & Chief of Staff||N/A||N/A||N/A|
|Mr. Michael Shine||Sr. VP of Commercial||N/A||N/A||N/A|
|Dr. Robert J. Hopkins FACP, M.D., M.P.H.||Chief Medical Officer||N/A||N/A||N/A|
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Ocugen, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 7. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 8; Compensation: 6.